Discover why Enphase Energy (ENPH) is now rated Buy despite recent declines. Learn how IRA credits and cash reserves could ...
Phio Pharmaceuticals shares were higher after the company reported positive pathology results for its Phase 1b Intasyl PH-762 trial. The stock was 32% higher, at $2.72. Shares are up 55% year to date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback